Sep 1, 2008
By:
Sarah Houlton
In order to take a big step forward, GSK looks to employ smaller licensing deals and business units
|
Aug 1, 2008
By:
Sarah Houlton
Britain's new approach to drug pricing isn't as bad as the industry feared.
|
Jun 1, 2008
By:
Sarah Houlton
EU makes plans to police its supply chain
|
Apr 1, 2008
By:
Sarah Houlton
Can ceasing trade sales and finding funding help UK biotechs became an industry in their own right?
|
UK agency taking the heat for slow evaluations and failing to consider societal benefits of new drugs
Mar 1, 2008
By:
Sarah Houlton
UK agency takes the heat for slow evaluations and failing to consider societal benefits of new drugs
|
UK agency worries that new pharma single-supplier practice will mean higher costs for NHS
Feb 1, 2008
By:
Sarah Houlton
Will the sole-wholesaler approach mean higher costs for NHS?
|
Pharma defends itself against claims made in charity's report on drug access for the world's poor
Jan 1, 2008
By:
Sarah Houlton
Pharma defends itself against claims made in charity's report on drug access for the world's poor
|
Will a new health council speed the introduction of innovative medicines in the United Kingdom?
Dec 1, 2007
By:
Sarah Houlton
One of industry's main complaints is that delaying the introduction of new medicines is a particularly simple way of saving money
|
Will CROs continue to operate in India, or will Novartis' pullout send them farther East?
Nov 1, 2007
By:
Sarah Houlton
Will CROs continue to operate in India, or will Novartis' pullout send them farther East?
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
